Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Publication
, Conference
Shah, NN; Maziarz, RT; Jacobson, CA; Johnston, PB; Abhyankar, S; Isufi, I; Perales, MA; Ghosh, M; Ulrickson, M; Rosenthal, AC; Munoz, JL ...
Published in: Blood
November 5, 2024
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
68 / 68
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Shah, N. N., Maziarz, R. T., Jacobson, C. A., Johnston, P. B., Abhyankar, S., Isufi, I., … Miklos, D. B. (2024). Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. In Blood (Vol. 144, pp. 68–68). American Society of Hematology. https://doi.org/10.1182/blood-2024-208539
Shah, Nirav N., Richard T. Maziarz, Caron A. Jacobson, Patrick B. Johnston, Sunil Abhyankar, Iris Isufi, Miguel Angel Perales, et al. “Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.” In Blood, 144:68–68. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-208539.
Shah NN, Maziarz RT, Jacobson CA, Johnston PB, Abhyankar S, Isufi I, et al. Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. In: Blood. American Society of Hematology; 2024. p. 68–68.
Shah, Nirav N., et al. “Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 68–68. Crossref, doi:10.1182/blood-2024-208539.
Shah NN, Maziarz RT, Jacobson CA, Johnston PB, Abhyankar S, Isufi I, Perales MA, Ghosh M, Ulrickson M, Rosenthal AC, Munoz JL, Hardy NM, Rapoport AP, Karmali R, Awan FT, McKinney MS, Horwitz M, Lunning M, Denlinger N, Ancukiewicz M, Nallewar M, Coleman KC, Eromosele E, Kaleta R, Theruvath J, Wijatyk A, Miklos DB. Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood. American Society of Hematology; 2024. p. 68–68.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
68 / 68
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology